Patients who received the GeneSight test achieved initial response and remission faster

Clinician access to the GeneSight test results has been shown to help improve remission and response rates for patients with major depressive disorder (MDD),[1,2,3] but data describing its impact over time is limited. Therefore, a post-hoc analysis of the PRIME Care trial was performed to determine whether access to the GeneSight test results increases the rate of remission and response over time in patients with MDD, and if so, to determine if the effect was persistent.

1,764 (90.7%) of the 1,944 veterans with MDD who participated in the PRIME Care trial had sufficient data to be included in this post-hoc analysis.

Key findings

Patients in the GeneSight arm had faster initial remission and response than those in the treatment as usual (TAU) arm.

- Patients in the GeneSight arm were 27% more likely to achieve remission at any given time during the 24-week study (HR=1.27, p=0.015)
- Patients in the GeneSight arm were 21% more likely to achieve response at any given time during the 24-week study (HR=1.21, p=0.010)

The benefit of GeneSight testing persisted over the 24-weeks of the study.

- The impact of the GeneSight test on likelihood to achieve remission and response compared to TAU did not vary significantly over the 24-week time frame, indicating a persistent effect of access to GeneSight testing on remission and response.

Not all patients who receive the GeneSight Psychotropic test will achieve response and/or remission or have faster initial response and/or remission, and not all will have a persistent effect.

Hain D, et al. Persistent benefit of pharmacogenomic testing on initial remission and response rates in patients with major depressive disorder. Front Pharmacol, 2025;16. https://doi.org/10.3389/fphar.2025.1658616

References:
1. Greden et al. J Psychiatr Res. 2019.
2. Oslin et al. JAMA. 2022.
3. Albers et al. J Clin Psychopharmacol. 2025.

Myriad genetics

© 2025 Myriad Genetics, Inc./Assurex Health, Inc. Myriad Genetics, GeneSight, and associated logos are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. GSPS.113.25X.

genesight